oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2020-19-3-156-163oncotomsk-1500Research ArticleОБЗОРЫREVIEWSИЗМЕНЕНИЯ ПАРАДИГМЫ ЛЕЧЕНИЯ БОЛЬНЫХ ОПЕРАБЕЛЬНЫМ РАКОМ ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫA PARADIGM SHIFT IN THE TREATMENT OF PATIENTS WITH RESECTABLE PANCREATIC CANCERАнтоноваЕ. Ю.AntonovaE. Yu.

аспирант, отделение химиотерапии № 1 торако-абдоминального отдела (химиотерапии № 17), НИИ КО им. Н.Н. Трапезникова,

115478, г. Москва, Каширское шоссе, 23

MD, Postgraduate, Thoracic and Abdominal Department,

23, Kashirskoe shosse, 115478-Moscow

elenaantonova5@mail.ruБазинИ. С.BazinI. S.

доктор медицинских наук, старший научный сотрудник отделения клинической фармакологии и химиотерапии, НИИ КО им. Н.Н. Трапезникова, 115478, г. Москва, Каширское шоссе, 23;

170100, г. Тверь, ул. Советская, 4

MD, Senior Researcher, Department of Clinical Pharmacology and Chemotherapy,

23, Kashirskoe shosse, 115478-Moscow,

4, Sovetskaya Street, 170100-Tver

ГаринА. М.GarinA. M.

профессор, главный научный сотрудник отделения клинической фармакологии и химиотерапии, НИИ КО им. Н.Н. Трапезникова,

115478, г. Москва, Каширское шоссе, 23

MD, Professor, Leading Researcher, Department of Clinical Pharmacology and Chemotherapy, 

23, Kashirskoe shosse, 115478-Moscow

https://orcid.org/0000-0001-9864-3837ПокатаевИ. А.PokataevI. A.

кандидат медицинских наук, научный сотрудник отделения клинической фармакологии и химиотерапии, НИИ КО им. Н.Н. Трапезникова,

115478, г. Москва, Каширское шоссе, 23

MD, PhD, Researcher, Department of Clinical Pharmacology and Chemotherapy, 

23, Kashirskoe shosse, 115478-Moscow

СагайдакИ. В.SagaidakI. B.

профессор, ведущий научный сотрудник, хирургическое отделение опухолей печени и поджелудочной железы № 7, НИИ КО им. Н.Н. Трапезникова,

115478, г. Москва, Каширское шоссе, 23

MD, Professor, Leading Researcher, Department of Surgery for Liver and Pancreas Tumors,

23, Kashirskoe shosse, 115478-Moscow

https://orcid.org/0000-0001-5348-5011ПоляковА. Н.PolyakovA. N.

кандидат медицинских наук, онколог-хирург, хирургическое отделение опухолей печени и поджелудочной железы № 7, НИИ КО им. Н.Н. Трапезникова,

115478, г. Москва, Каширское шоссе, 23

MD, PhD, Oncologist-Surgeon, Department of Surgery for Liver and Pancreas Tumors,

23, Kashirskoe shosse, 115478-Moscow

ЧихареваЯ. Е.ChiharevaY. E.

клинический ординатор, отделения химиотерапии и комбинированного лечения злокачественных опухолей, НИИ КО им. Н.Н. Трапезникова,

115478, г. Москва, Каширское шоссе, 23

MD, Clinical Resident, Department of Chemotherapy and Combined Treatment of Malignant Tumors,

23, Kashirskoe shosse, 115478-Moscow

ВолковА. Ю.VolkovA. Yu.

аспирант, хирургическое отделение № 6 (абдоминальной онкологии) торако-абдоминального отдела, НИИ КО им. Н.Н. Трапезникова,

115478, г. Москва, Каширское шоссе, 23

MD, Postgraduate, Thoracic and Abdominal Department, 

23, Kashirskoe shosse, 115478-Moscow

БазинаИ. В.BazinaI. V.

кандидат технических наук, доцент кафедры физики и математики ПФ?

117997, г. Москва, ул. Островитянова, 1

PhD, Associate Professor,

1, Ostrovityanova Street, 117997-Moscow

ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian FederationФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России; ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of Oncology; Tver State Medical UniversityRussian FederationФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава РоссииРоссияPirogov Russian National Research Medical UniversityRussian Federation202006072020193156163Copyright © Антонова Е.Ю., Базин И.С., Гарин А.М., Покатаев И.А., Сагайдак И.В., Поляков А.Н., Чихарева Я.Е., Волков А.Ю., Базина И.В., 20202020Антонова Е.Ю., Базин И.С., Гарин А.М., Покатаев И.А., Сагайдак И.В., Поляков А.Н., Чихарева Я.Е., Волков А.Ю., Базина И.В.Antonova E.Y., Bazin I.S., Garin A.M., Pokataev I.A., Sagaidak I.B., Polyakov A.N., Chihareva Y.E., Volkov A.Y., Bazina I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1500

Цель исследования – предоставить онкологам и хирургам, специализирующимся на лечении больных раком поджелудочной железы, наиболее полную информацию о значении и роли химиотерапии в лечении пациентов, страдающих операбельным и погранично-резектабельным раком поджелудочной железы, на основе последних литературных данных.

Материал и методы

Материал и методы. Поиск информационных источников произведен в системах Pubmed, COSMIC cancer database. Проанализированы отчеты органов исполнительной власти в сфере здравоохранения субъектов Российской Федерации, мировые источники, содержащие сведения по заболеваемости, смертности, одногодичной летальности больных с диагнозом рак поджелудочной железы. Проанализированы данные ретроспективных и проспективных клинических исследований. В работе отражен опыт российских и зарубежных исследователей.

Результаты

Результаты. На основании анализа наиболее актуальных публикаций последних лет представлены данные по современным подходам к лечению операбельного рака поджелудочной железы.

Заключение

Заключение. Представленные в статье данные обобщают материалы клинических исследований последних лет. Это, в свою очередь, позволит онкологам выбрать наиболее правильную и персонализированную тактику ведения пациентов с операбельным и условно операбельным раком поджелудочной железы. 

Purpose of the study was to provide medical oncologists and surgeons specializing in the treatment of pancreatic cancer patients with the most recent information on the importance and role of chemotherapy in the treatment of patients with resectable and borderline resectable pancreatic cancer.

Material and Methods

Material and Methods. Pubmed and COSMIC databases were used for literature search. Reports of the executive authorities in the field of Health Care of the Russian Federation, as well as worldwide data regarding morbidity and mortality of patients with pancreatic cancer were analyzed. The data of retrospective and prospective clinical trials were studied.

Results

Results. Based on the analysis of the most recent publications, the authors provided data on modern approaches to the treatment of operable pancreatic cancer.

Conclusion

Conclusion. The data presented in the article summarize results of recent clinical trials. This will allow oncologists to choose the most correct and personalized tactics for the management of patients with resectable and borderline resectable pancreatic cancer. 

рак поджелудочной железызаболеваемостьадъювантная химиотерапиянеоадъювантная химиотерапияpancreatic cancerincidenceadjuvant chemotherapyneoadjuvant chemotherapyReferencesBray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424. doi:10.3322/caac.21492.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424. doi:10.3322/caac.21492.McGuigan A., Kelly P., Turkington R.C., Jones C., Coleman H.G., McCain R.S. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846–4861. doi: 10.3748/wjg.v24.i43.4846.McGuigan A., Kelly P., Turkington R.C., Jones C., Coleman H.G., McCain R.S. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846–4861. doi: 10.3748/wjg.v24.i43.4846.Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Bray F. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer [Internet]. URL: http://gco.iarc.fr/tomorrow/graphic-isotype?type=1&population=900&mode=population&sex=0&cancer=39&age_group=value&apc_male=0&apc_female=0 (cited 23.06.2019).Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Bray F. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer [Internet]. URL: http://gco.iarc.fr/tomorrow/graphic-isotype?type=1&population=900&mode=population&sex=0&cancer=39&age_group=value&apc_male=0&apc_female=0 (cited 23.06.2019).Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. М., 2018. С. 86–89.Kaprin A.D., Starinsky V.V., Petrova G.V. The status of cancer care for the population of Russia in 2017. Moscow, 2018. P. 86–89 (in Russian).Ассоциация онкологов России. Рак поджелудочной железы. Клинические рекомендации. 2017. 35 с.Russian Oncology Association. Pancreas cancer. Clinical recommendations. 2017. 35 p. (in Russian).Duell E.J., Lucenteforte E., Olson S.H., Bracci P.M., Li D., Risch H.A., Fontham E.H. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012; 23(11): 2964–2970. doi: 10.1093/annonc/mds140.Duell E.J., Lucenteforte E., Olson S.H., Bracci P.M., Li D., Risch H.A., Fontham E.H. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012; 23(11): 2964–2970. doi: 10.1093/annonc/mds140.Huang Y., Cai X., Qiu M., Chen P., Tang H., Hu Y., Huang Y. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014; 57(11): 2261–9. doi: 10.1007/s00125-014-3361-2.Huang Y., Cai X., Qiu M., Chen P., Tang H., Hu Y., Huang Y. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014; 57(11): 2261–9. doi: 10.1007/s00125-014-3361-2.Wolpin B.M., Ng K., Bao Y., Kraft P., Stampfer M.J., Michaud D.S., Rifai N. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21(1): 82–91. doi: 10.1158/1055-9965.EPI-11-0836.Wolpin B.M., Ng K., Bao Y., Kraft P., Stampfer M.J., Michaud D.S., Rifai N. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21(1): 82–91. doi: 10.1158/1055-9965.EPI-11-0836.Lynch S.M., Vrieling A., Lubin J.H., Kraft P., Mendelsohn J.B., Hartge P., Canzian F., Steplowski E., Arslan A.A., Gross M., Helzlsouer K., Jacobs E.J., LaCroix A., Petersen G., Zheng W., Albanes .D, Amundadottir L., Bingham S.A., Boffetta P., Boutron-Ruault M.C., Chanock S.J., Clipp S., Hoover R.N., Jacobs K., Johnson K.C., Kooperberg C., Luo J., Messina C., Palli D., Patel A.V., Riboli E., Shu X.O., Rodriguez Suarez L., Thomas G., Tjønneland A., Tobias G.S., Tong E., Trichopoulos D., Virtamo J., Ye W., Yu K., Zeleniuch-Jacquette A., Bueno-de-Mesquita H.B., StolzenbergSolomon R.Z. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol. 2009; 170(4): 403–13. doi: 10.1093/aje/kwp134.Lynch S.M., Vrieling A., Lubin J.H., Kraft P., Mendelsohn J.B., Hartge P., Canzian F., Steplowski E., Arslan A.A., Gross M., Helzlsouer K., Jacobs E.J., LaCroix A., Petersen G., Zheng W., Albanes .D, Amundadottir L., Bingham S.A., Boffetta P., Boutron-Ruault M.C., Chanock S.J., Clipp S., Hoover R.N., Jacobs K., Johnson K.C., Kooperberg C., Luo J., Messina C., Palli D., Patel A.V., Riboli E., Shu X.O., Rodriguez Suarez L., Thomas G., Tjønneland A., Tobias G.S., Tong E., Trichopoulos D., Virtamo J., Ye W., Yu K., Zeleniuch-Jacquette A., Bueno-de-Mesquita H.B., StolzenbergSolomon R.Z. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol. 2009; 170(4): 403–13. doi: 10.1093/aje/kwp134.Базин И.С., Соловьяненко М.А., Насырова Р.Ю., Подлужный Д., Костякова Л., Гарин А.М. Лекарственная терапия в современном лечении рака поджелудочной железы. Эффективная фармакотерапия. 2011; 24: 30–34.Bazin I.S., Solovyanenko M.A., Nasyrova R.Yu., Podluzhny D., Kostyakova L., Garin A.M. Drug therapy in the presence of pancreatic cancer. Effective Pharmacotherapy. 2011; 24: 30–34. (in Russian).Van Tienhoven G., Versteijne E., Suker M., Groothuis K.B., Busch O.R., Bonsing B.A., Zwinderman A.H. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018; 36(18_suppl.). doi: 10.1200/JCO.2018.36.18_suppl.LBA4002.Van Tienhoven G., Versteijne E., Suker M., Groothuis K.B., Busch O.R., Bonsing B.A., Zwinderman A.H. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018; 36(18_suppl.). doi: 10.1200/JCO.2018.36.18_suppl.LBA4002.Howard T.J., Krug J.E., Yu J., Zyromski N.J., Schmidt C.M., Jacobson L.E., Madura J.A., Wiebke E.A., Lillemoe K.D. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg. 2006 Dec; 10(10): 1338–45. doi: 10.1016/j.gassur.2006.09.008.Howard T.J., Krug J.E., Yu J., Zyromski N.J., Schmidt C.M., Jacobson L.E., Madura J.A., Wiebke E.A., Lillemoe K.D. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg. 2006 Dec; 10(10): 1338–45. doi: 10.1016/j.gassur.2006.09.008.Jang J.Y., Han Y., Lee H., Kim S.W., Kwon W., Lee K.H., Oh D.Y., Chie E.K., Lee J.M., Heo J.S., Park J.O., Lim D.H., Kim S.H., Park S.J., Lee W.J., Koh Y.H., Park J.S., Yoon D.S., Lee I.J., Choi S.H. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg. 2018 Aug; 268(2): 215–222. doi: 10.1097/SLA.0000000000002705.Jang J.Y., Han Y., Lee H., Kim S.W., Kwon W., Lee K.H., Oh D.Y., Chie E.K., Lee J.M., Heo J.S., Park J.O., Lim D.H., Kim S.H., Park S.J., Lee W.J., Koh Y.H., Park J.S., Yoon D.S., Lee I.J., Choi S.H. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg. 2018 Aug; 268(2): 215–222. doi: 10.1097/SLA.0000000000002705.Reni M., Balzano G., Zanon S., Zerbi A., Rimassa L., Castoldi R., Pinelli D., Mosconi S., Doglioni C., Chiaravalli M., Pircher C., Arcidiacono P.G., Torri V., Maggiora P., Ceraulo D., Falconi M., Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018; 3(6): 413–423. doi: 10.1016/S2468-1253(18)30081-5.Reni M., Balzano G., Zanon S., Zerbi A., Rimassa L., Castoldi R., Pinelli D., Mosconi S., Doglioni C., Chiaravalli M., Pircher C., Arcidiacono P.G., Torri V., Maggiora P., Ceraulo D., Falconi M., Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018; 3(6): 413–423. doi: 10.1016/S2468-1253(18)30081-5.Bilimoria K.Y., Talamonti M.S., Sener S.F., Bilimoria M.M., Stewart A.K., Winchester D.P., Ko C.Y., Bentrem D.J. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg. 2008 Oct; 207(4): 510–9. doi: 10.1016/j.jamcollsurg.2008.04.033.Bilimoria K.Y., Talamonti M.S., Sener S.F., Bilimoria M.M., Stewart A.K., Winchester D.P., Ko C.Y., Bentrem D.J. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg. 2008 Oct; 207(4): 510–9. doi: 10.1016/j.jamcollsurg.2008.04.033.Winter J.M., Cameron J.L., Campbell K.A., Arnold M.A., Chang D.C., Coleman J., Hodgin M.B., Sauter P.K., Hruban R.H., Riall T.S., Schulick R.D., Choti M.A., Lillemoe K.D., Yeo C.J. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006 Nov; 10(9): 1199–210. doi: 10.1016/j.gassur.2006.08.018.Winter J.M., Cameron J.L., Campbell K.A., Arnold M.A., Chang D.C., Coleman J., Hodgin M.B., Sauter P.K., Hruban R.H., Riall T.S., Schulick R.D., Choti M.A., Lillemoe K.D., Yeo C.J. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006 Nov; 10(9): 1199–210. doi: 10.1016/j.gassur.2006.08.018.Zervos E.E., Rosemurgy A.S., Al-Saif O., Durkin A.J. Surgical management of early-stage pancreatic cancer. Cancer Control. 2004 JanFeb; 11(1): 23–31. doi: 10.1177/107327480401100104.Zervos E.E., Rosemurgy A.S., Al-Saif O., Durkin A.J. Surgical management of early-stage pancreatic cancer. Cancer Control. 2004 JanFeb; 11(1): 23–31. doi: 10.1177/107327480401100104.Cameron J.L., Riall T.S., Coleman J., Belcher K.A. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006 Jul; 244(1): 10–5. doi: 10.1097/01.sla.0000217673.04165.ea.Cameron J.L., Riall T.S., Coleman J., Belcher K.A. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006 Jul; 244(1): 10–5. doi: 10.1097/01.sla.0000217673.04165.ea.Talamonti M. Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol. 2006 Aug; 13(8): 1019–20. doi: 10.1245/ASO.2006.02.902.Talamonti M. Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol. 2006 Aug; 13(8): 1019–20. doi: 10.1245/ASO.2006.02.902.Varadhachary G.R., Tamm E.P., Abbruzzese J.L., Xiong H.Q., Crane C.H., Wang H., Lee J.E., Pisters P.W., Evans D.B., Wolff R.A. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006 Aug; 13(8): 1035–46. doi: 10.1245/ASO.2006.08.011.Varadhachary G.R., Tamm E.P., Abbruzzese J.L., Xiong H.Q., Crane C.H., Wang H., Lee J.E., Pisters P.W., Evans D.B., Wolff R.A. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006 Aug; 13(8): 1035–46. doi: 10.1245/ASO.2006.08.011.Покатаев И.А., Алиева С.Б., Гладков О.А., Загайнов В.Е., Кудашкин Н.Е., Патютко Ю.И., Трякин А.А. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO. 2018; 8(3-s2): 401–413.Pokataev I.A., Alieva B.B., Gladkov O.A., Zagainov V.E., Kudashkin N.E., Patyutko Yu.I., Tryakin A.A. Practical recommendations for the treatment of pancreatic cancer glands. Malignant tumors: Practical recommendations of RUSSCO. 2018; 8 (3-s2): 401–413. (in Russian).Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Büchler M.W.; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar 18; 350(12): 1200–10. doi: 10.1056/NEJMoa032295.Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Büchler M.W.; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar 18; 350(12): 1200–10. doi: 10.1056/NEJMoa032295.Crane C.H., Ben-Josef E., Small W.Jr. Chemotherapy for pancreatic cancer. N Engl J Med. 2004 Jun 24; 350(26): 2713–5.Crane C.H., Ben-Josef E., Small W.Jr. Chemotherapy for pancreatic cancer. N Engl J Med. 2004 Jun 24; 350(26): 2713–5.Koshy M.C., Landry J.C., Cavanaugh S.X., Fuller C.D., Willett C.G., Abrams R.A., Hoffman J.P., Thomas C.R.Jr. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4): 965–6. doi: 10.1016/j.ijrobp.2004.11.018.Koshy M.C., Landry J.C., Cavanaugh S.X., Fuller C.D., Willett C.G., Abrams R.A., Hoffman J.P., Thomas C.R.Jr. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4): 965–6. doi: 10.1016/j.ijrobp.2004.11.018.Morris S.L., Beasley M., Leslie M. Chemotherapy for pancreatic cancer. N Engl J Med. 2004; 350(26): 2713–5. doi: 10.1056/NEJM200406243502617.Morris S.L., Beasley M., Leslie M. Chemotherapy for pancreatic cancer. N Engl J Med. 2004; 350(26): 2713–5. doi: 10.1056/NEJM200406243502617.Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., Schmalenberg H., Weigang-Koehler K., Bechstein W.O., Niedergethmann M., Schmidt-Wolf I., Roll L., Doerken B., Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17; 297(3): 267–77. doi: 10.1001/jama.297.3.267.Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., Schramm H., Fahlke J., Zuelke C., Burkart C., Gutberlet K., Kettner E., Schmalenberg H., Weigang-Koehler K., Bechstein W.O., Niedergethmann M., Schmidt-Wolf I., Roll L., Doerken B., Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17; 297(3): 267–77. doi: 10.1001/jama.297.3.267.Neuhaus P., Riess H., Post S., Gellert K., Ridwelski K., Schramm H., Oettle H. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol. 2008; 26(15_suppl.): LBA4504-LBA4504.Neuhaus P., Riess H., Post S., Gellert K., Ridwelski K., Schramm H., Oettle H. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol. 2008; 26(15_suppl.): LBA4504-LBA4504.Neoptolemos J.P., Stocken D.D., Bassi C., Ghaneh P., Cunningham D., Goldstein D., Padbury R., Moore M.J., Gallinger S., Mariette C., Wente M.N., Izbicki J.R., Friess H., Lerch M.M., Dervenis C., Oláh A., Butturini G., Doi R., Lind P.A., Smith D., Valle J.W., Palmer D.H., Buckels J.A., Thompson J., McKay C.J., Rawcliffe C.L., Büchler M.W.; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8; 304(10): 1073–81. doi: 10.1001/jama.2010.1275.Neoptolemos J.P., Stocken D.D., Bassi C., Ghaneh P., Cunningham D., Goldstein D., Padbury R., Moore M.J., Gallinger S., Mariette C., Wente M.N., Izbicki J.R., Friess H., Lerch M.M., Dervenis C., Oláh A., Butturini G., Doi R., Lind P.A., Smith D., Valle J.W., Palmer D.H., Buckels J.A., Thompson J., McKay C.J., Rawcliffe C.L., Büchler M.W.; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8; 304(10): 1073–81. doi: 10.1001/jama.2010.1275.Neoptolemos J.P., Palmer D., Ghaneh P., Valle J.W., Cunningham D., Wadsley J., Segersvard R. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2016; 34(18suppl). doi: 10.1200/JCO.2016.34.18_suppl.LBA4006.Neoptolemos J.P., Palmer D., Ghaneh P., Valle J.W., Cunningham D., Wadsley J., Segersvard R. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2016; 34(18suppl). doi: 10.1200/JCO.2016.34.18_suppl.LBA4006.Neoptolemos J.P., Moore M.J., Cox T.F., Valle J.W., Palmer D.H., McDonald A.C., Carter R., Tebbutt N.C., Dervenis C., Smith D., Glimelius B., Charnley R.M., Lacaine F., Scarfe A.G., Middleton M.R., Anthoney A., Ghaneh P., Halloran C.M., Lerch M.M., Oláh A., Rawcliffe C.L., Verbeke C.S., Campbell F., Büchler M.W.; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11; 308(2): 147–56. doi: 10.1001/jama.2012.7352.Neoptolemos J.P., Moore M.J., Cox T.F., Valle J.W., Palmer D.H., McDonald A.C., Carter R., Tebbutt N.C., Dervenis C., Smith D., Glimelius B., Charnley R.M., Lacaine F., Scarfe A.G., Middleton M.R., Anthoney A., Ghaneh P., Halloran C.M., Lerch M.M., Oláh A., Rawcliffe C.L., Verbeke C.S., Campbell F., Büchler M.W.; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11; 308(2): 147–56. doi: 10.1001/jama.2012.7352.Oettle H., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zülke C., Fahlke J., Arning M.B., Sinn M., Hinke A., Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013 Oct 9; 310(14): 1473–81. doi: 10.1001/jama.2013.279201.Oettle H., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zülke C., Fahlke J., Arning M.B., Sinn M., Hinke A., Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013 Oct 9; 310(14): 1473–81. doi: 10.1001/jama.2013.279201.Conroy T., Hammel P., Hebbar M., Ben Abdelghani M., Wei A.C.C., Raoul J.L., Lecomte T. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol. 2018; 36(18_suppl.). doi: 10.1200/JCO.2018.36.18_suppl.LBA4001.Conroy T., Hammel P., Hebbar M., Ben Abdelghani M., Wei A.C.C., Raoul J.L., Lecomte T. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol. 2018; 36(18_suppl.). doi: 10.1200/JCO.2018.36.18_suppl.LBA4001.Breslin T.M., Hess K.R., Harbison D.B., Jean M.E., Cleary K.R., Dackiw A.P., Vauthey J.N. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8: 123–132.Breslin T.M., Hess K.R., Harbison D.B., Jean M.E., Cleary K.R., Dackiw A.P., Vauthey J.N. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8: 123–132.Покатаев И.А. Обзор новых исследований, способных изменить клиническую практику при раке поджелудочной железы. Злокачественные опухоли 2018; 3s1: 76–81. doi: 10.18027/2224-5057-2018-8-3s1-76-81.Pokataev I.A. A review of new studies that can change the clinical practice of pancreatic cancer. Malignant tumors 2018; 3s1: 76–81. (in Russian)]. doi: 10.18027/2224-5057-2018-8-3s1-76-81.Van Tienhoven G., Versteijne E., Suker M., Groothuis K.B., Busch O.R., Bonsing B.A., Zwinderman A.H. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018; 36(18_suppl.). doi: 10.1200/JCO.2018.36.18_suppl.LBA4002.Van Tienhoven G., Versteijne E., Suker M., Groothuis K.B., Busch O.R., Bonsing B.A., Zwinderman A.H. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J Clin Oncol. 2018; 36(18_suppl.). doi: 10.1200/JCO.2018.36.18_suppl.LBA4002.Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988 Jul 20; 80(10): 751–5.Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988 Jul 20; 80(10): 751–5.Chauffert B., Mornex F., Bonnetain F., Rougier P., Mariette C., Bouché O., Bosset J.F., Aparicio T., Mineur L., Azzedine A., Hammel P., Butel J., Stremsdoerfer N., Maingon P., Bedenne L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008 Sep; 19(9): 1592–9. doi: 10.1093/annonc/mdn281.Chauffert B., Mornex F., Bonnetain F., Rougier P., Mariette C., Bouché O., Bosset J.F., Aparicio T., Mineur L., Azzedine A., Hammel P., Butel J., Stremsdoerfer N., Maingon P., Bedenne L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008 Sep; 19(9): 1592–9. doi: 10.1093/annonc/mdn281.Motoi F., Kosuge T., Ueno H., Yamaue H., Satoi S., Sho M., Honda G., Matsumoto I., Wada K., Furuse J., Matsuyama Y., Unno M.; Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019 Feb 1; 49(2): 190194. doi: 10.1093/jjco/hyy190.Motoi F., Kosuge T., Ueno H., Yamaue H., Satoi S., Sho M., Honda G., Matsumoto I., Wada K., Furuse J., Matsuyama Y., Unno M.; Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019 Feb 1; 49(2): 190194. doi: 10.1093/jjco/hyy190.

The authors declare that there are no conflicts of interest present.